Company Profile
Embecta Stock Price, News & Analysis
- Ticker:
- EMBC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.50 USD (-1.96%)
Close
Last updated: August 6, 2026
207M USD
Market cap
Why the stock is moving
The latest monitored company update is “Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Global Diabetes Care
Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management.
Injection-Device Portfolio
The company's core portfolio includes pen needles and syringes, with market-specific products moving through U.S. and European regulatory review. These high-volume consumables serve both branded diabetes therapies and a growing market for injectable GLP-1 medicines.
Owen Mumford Expansion
The acquisition of Owen Mumford broadens Embecta's drug-delivery capabilities and product range. The company also works with pharmaceutical partners to co-package its pen needles with generic GLP-1 therapies in multiple international markets.
Future catalysts
Regulatory outcomes for market-appropriate pen needles under review by the FDA and for CE Mark certification.
Market-appropriate syringe launches in selected geographies in the coming months.
U.S. launch of a GLP-1 small-pack format in the fourth quarter of fiscal 2026.
Recent news
- 01
- 02
embecta Announces Quarterly Cash Dividend
Source: Embecta
- 03
embecta to Report Fiscal Third Quarter Financial Results
Source: Embecta
- 04
- 05
embecta to Participate in Investor Events
Source: Embecta
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Embecta (EMBC)?
Embecta (EMBC) most recently closed at 3.50 USD, a -1.96% move versus the previous session.
What is the market cap of Embecta (EMBC)?
Embecta currently has a market capitalization of 207M USD on BioPharmSignal.
What does Embecta do?
Global Diabetes Care Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management. Injection-Device Portfolio The company's core portfolio includes pen needles and syringes, with...
On which exchange is EMBC stock listed?
Embecta (EMBC) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
launch of a GLP-1 small-pack format in the fourth quarter of fiscal 2026.
Which conditions is Embecta targeting with GLP-1?
Embecta is associated with diabetes based on its company overview and current catalyst commentary.
How does Embecta describe recent progress with GLP-1?
launch of a GLP-1 small-pack format in the fourth quarter of fiscal 2026.
What is Global?
Global Diabetes Care Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery.